Makoto Tahara, ESMO 2022: 5-year results from KEYNOTE-048 – Pembrolizumab for treatment of recurrent/metastatic head and neck squamous cell carcinoma
Long-term follow-up (4 years) of the phase 3 KEYNOTE-048 (NCT02358031) study continued to demonstrate survival benefit with pembrolizumab monotherapy and pembrolizumab + chemotherapy vs EXTREME in first-line recurrent/metastatic head and neck squamous cell carcinoma. Dr Makoto Tahara(Cliniques Universitaires Saint-Luc, Brussels, Belgium) joins touchONCOLOGY to discuss 5 years of follow-up in patients from KEYNOTE-048, and the further investigations that are needed to optimise the use of pembrolizumab in this treatment setting.
The abstract entitled ‘Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048‘ Abstract 659MO, was presented at European Society for Medical Oncology (ESMO) 2022.
Questions:
- What did the KEYNOTE-048 study teach us about the efficacy and safety of pembrolizumab in recurrent or metastatic head and neck squamous cell carcinoma? (0:14)
- What have been the study findings at 5 years, and what is their clinical significance? (1:26)
- What further investigations are needed to optimise the use of pembrolizumab in this treatment setting? (1:51)
Disclosures: Makoto Tahara is an Advisory board member for Ono Pharmaceutical, BMS, Bayer, MSD, Eli Lilly, GSK, Pfizer, AstraZeneca, Rakuten Medical and Merck Biopharma; and receives honoraria/honorarium from Ono Pharmaceutical, BMS, Bayer, MSD, Eli Lilly, Rakuten Medical and Merck Biopharma.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
